Overactive bladder syndrome
NGF and HB EGF: Potential Biomarkers that Reflect the Effects of Fesoterodine in Patients with Overactive Bladder Syndrome
8
Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome
13
How long do we have to treat overactive bladder syndrome? A questionnaire survey of Canadian urologists and gynecologists
13
The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection
7
Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: a prospective comparative study
5
Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
10
How long do we have to treat overactive bladder syndrome? A questionnaire survey of Canadian urologists and gynecologists
6
Overactive bladder, differential diagnosis, and clinical utility of fesoterodine
9
Percutaneous tibial nerve stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review
11
Profile of mirabegron in the treatment of overactive bladder: place in therapy
5
Treatment of overactive bladder in the aging population: focus on darifenacin
8
<p>Is There a Link Between Carotid Atherosclerosis and Idiopathic Overactive Bladder Among Women with Metabolic Syndrome?</p>
6
Urodynamic Patterns of the Idiopathic Overactive Bladder
6
Translating Overactive Bladder Questionnaires in Moroccan Arabic Dialect
13
Prevalence of overlap syndromes and symptoms in pediatric functional dyspepsia
6
Fesoterodine for the treatment of urinary incontinence and overactive bladder
8
OnabotulinumtoxinA in the treatment of neurogenic bladder
8
Receptor pharmacology and other relevant factors in lower urinary tract pathology under a functional and toxicological approach: Instrument to better manage antimicrobials therapy
45
Oxybutynin topical gel in the treatment of overactive bladder
8
Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA
9